Background {#Sec1}
==========

Atrial fibrillation (AF) is the most common complication and the most common arrhythmia detected following cardiac surgery \[[@CR1]--[@CR4]\]. The incidence of AF in patients after cardiac surgery has been reported to range between 15 and 50 % \[[@CR5]--[@CR7]\], with patients undergoing valve surgery being at the greatest risk \[[@CR8]\]. In addition, AF most commonly occurs within 4 days postoperatively \[[@CR5], [@CR8]\]. Postoperative AF is associated with a prolonged hospital stay, higher costs, and increased morbidity and mortality \[[@CR4]--[@CR8]\].

Although a number of prophylactic strategies for the prevention of postoperative AF have been proposed, they are not routinely implemented in many clinical centers \[[@CR9], [@CR10]\], including ours. The major reasons for non-use include a lack of convincing evidence, potential risks associated with current drug therapies, and complexity of some prevention regimens \[[@CR11], [@CR12]\]. Sedatives and analgesics are routinely administered to most patients undergoing cardiac surgery to reduce anxiety and pain \[[@CR13], [@CR14]\]. Dexmedetomidine has been used as a safe and efficacious sedative agent in patients undergoing cardiac surgery \[[@CR15], [@CR16]\], without pro-tachyarrhythmic or negative inotropic effects \[[@CR17]\]. Moreover, dexmedetomidine is associated with decreased incidence of postoperative supraventricular and ventricular tachyarrhythmia and has been found to terminate supraventricular tachycardia in pediatric patients \[[@CR18]--[@CR20]\]. Recently, two retrospective studies also showed that dexmedetomidine sedation might decrease atrial arrhythmia in adult patients after cardiovascular surgery \[[@CR21], [@CR22]\]. It appears that dexmedetomidine sedation would be a good choice for the prevention of postoperative AF. However, previous studies have been subject to selection bias and many confounders due to the observational design. Furthermore, the aforementioned studies did not directly compare dexmedetomidine with propofol, which is used in current standard practice for sedation after cardiac surgery.

We designed and implemented a prospective randomized controlled trial (RCT) to determine whether dexmedetomidine reduces the incidence of postoperative AF while effectively sedating mechanically ventilated patients after cardiac surgery, when compared to propofol sedation.

Methods {#Sec2}
=======

Patient population {#Sec3}
------------------

This prospective randomized controlled clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University and registered at chictr.org.cn (ChiCTR-IPR-16008231). This study was conducted in the First Affiliated Hospital of Zhejiang University between January 2015 and December 2015. Written informed consent was obtained from the patient or next of kin before enrollment. The inclusion criteria were as follows: age ≥18 years, elective cardiac surgery with cardiopulmonary bypass (CPB), admitted to intensive care unit (ICU) while intubated and ventilated, and lack of prior AF or flutter before receiving sedation in the ICU. Patients were excluded when they had at least one of the following characteristics at arrival in the ICU: heart rate \<50 beats per minute, atrioventricular conduction block of grade II or III (unless a pacemaker had been installed), mean arterial pressure (MAP) \<55 mmHg (despite appropriate intravenous volume replacement and vasopressor treatment), acute severe neurological disorder, propofol or dexmedetomidine allergy or other contraindications. In addition, patients who had received two or more sedatives within 24 h postoperatively were also excluded.

Randomization, masking and intervention {#Sec4}
---------------------------------------

Patients received standard anesthesia including induction with midazolam and sufentanil and paralysis with cisatracurium and maintenance with sevoflurane, propofol and sufentanil. During CPB, the administration of sevoflurane was stopped. The bypass circuit was primed with 1000 mL of lactated Ringer solution, 100 mL of 5 % sodium bicarbonate and 200 mL of 20 % mannitol. Prior to aortic cannulation, heparin was adjusted to maintain an activated clotting time longer than 450 seconds. The pump flow rates ranged from 1.8 to 2.4 L/min/m^2^. The core temperature was controlled at 32 to 34 °C using a heat exchanger in the bypass circuit. After surgery, the patients were transferred to the ICU. Upon arrival at the ICU, the patient's blood pressure, electrocardiograms and oxygen saturation were monitored. The patients were randomized in a 1:1 ratio to receive sedation with either propofol (control) or dexmedetomidine according to the random number table.

Dexmedetomidine or propofol was continuously infused without a loading dose. Sedation levels were evaluated with the Richmond agitation-sedation scale (RASS), which ranges from −5 (unarousable) to 4 (combative). An assessment of RASS was performed every 2 h or more often if required (e.g., if the patient's condition changed). The intravenous infusion speed of dexmedetomidine (≤1.5 μg/kg/h) or propofol (≤3 mg/kg/h) was adjusted to maintain RASS values between 0 and -3 \[[@CR23], [@CR24]\]. When hypotension (MAP \<65 mmHg) and/or bradycardia (heart rate \<60 beats/minute) lasted longer than 5 minutes, the infusion of the sedative was stopped until the patient exhibited blood pressure and heart rate within an acceptable range. The infusion of the sedative was stopped before extubation at the discretion of the attending physicians.

Sufentanil was continuously infused (usually at a rate of 0.06 μg/kg/h) for intravenous analgesia and discontinued until a total dose of 200 μg had been administered. Pain was assessed using the visual analog scale (VAS) (range 0 (no pain) to 10 (maximal pain)). If the VAS score was \>3 \[[@CR25]\], additional analgesia (morphine or tramadol) was provided.

Outcome measures {#Sec5}
----------------

The primary outcome was the incidence of AF within 96 h of surgery. Postoperative AF was defined as no consistent P waves before each QRS complex and an irregular ventricular rate \[[@CR3]\]. Each patient underwent continuous electrocardiographic monitoring for at least 96 h after surgery. The investigators recorded the time of AF onset when they detected AF on the electrocardiogram displayed on the bedside monitor, and a twelve-lead electrocardiographic recording was performed to confirm the rhythm if necessary. AF episodes lasting longer than 5 minutes were recorded \[[@CR3]\].

Adverse events recorded during the ICU stay included: bradycardia (heart rate \<60 beats/minute for \>5 minutes \[[@CR26]\]), hypotension (MAP \<65 mmHg for \>3 minutes), and postoperative nausea/vomiting and delirium (identified with a confusion assessment method for the ICU). Acute kidney injury was diagnosed according to Acute Kidney Injury Network (AKIN) criteria: an absolute increase in serum creatinine ≥26.4 μmol/L, percentage increase in serum creatinine ≥50 % (1.5-fold from baseline), or urine output \<0.5 ml/kg/h for \>6 h within 48 h after surgery \[[@CR27]\]. The intubation time (time from ICU admission to the time of extubation), length of ICU stay, length of (postoperative) hospital stay and hospital fees were also recorded.

Statistical analysis {#Sec6}
--------------------

Sample size determination was based on an expected 35 % occurrence of postoperative AF in the propofol group and an expected 10 % occurrence of AF in the dexmedetomidine group \[[@CR11], [@CR22], [@CR28]\]. At a significance level of 0.05 with a power of 0.80, the resulting sample size was 40 patients in each group. Anticipating a dropout rate of approximately 10 %, a sample size of 45 patients in each group was considered to be appropriate. Data were described using descriptive statistics and presented as the median (interquartile range) unless indicated otherwise. All continuous variables were analyzed using the Mann-Whitney *U* test due to the relatively small numbers. Categorical variables were compared using the Fisher exact test. Kaplan-Meier curves were generated for postoperative AF. SPSS (SPSS 16.0 for Windows; SPSS, Chicago, IL, USA) and GraphPad Prism 5.04 (GraphPad Software, La Jolla, CA, USA) were used for statistical analyses. A *P* value \<0.05 (two-sided) was regarded as statistically significant.

Results {#Sec7}
=======

A total of 479 patients were assessed for eligibility after cardiac surgery with CPB (Fig. [1](#Fig1){ref-type="fig"}). After 389 patients were excluded, 90 patients were randomly assigned to two groups: 45 patients received propofol and 45 patients received dexmedetomidine. One patient in each group was also infused with the other sedative within 24 h after surgery. Therefore, 44 patients in each group were included in the analysis. There were no differences between the groups in baseline demographic and surgical characteristics (Table [1](#Tab1){ref-type="table"}).Fig. 1Consort flow diagram of the study participantsTable 1Baseline demographic and surgical characteristics of the study populationCharacteristicsPropofol (n = 44)Dexmedetomidine (*n* = 44)*P* valueAge, years56.5 (49.3--62.0)53.0 (46.0--63.0)0.314Female gender30 (68.2)23 (52.3)0.191Body mass index, kg/m^2^21.8 (20.0--25.1)22.4 (20.8--24.6)0.607Hypertension13 (29.5)13 (29.5)\>0.999Diabetes5 (11.4)6 (13.6)\>0.999Smoking history10 (22.7)18 (40.9)0.108Chronic obstructive pulmonary disease2 (4.5)4 (9.1)0.676Left ventricular ejection fraction, %65.0 (57.0--71.0)65.0 (56.8--71.0)0.975New York Heart Association class0.561 I2 (4.5)2 (4.5) II28 (63.6)29 (65.9) III12 (27.3)13 (29.5) IV2 (4.5)0 (0)Preoperative use of β-blockers5 (11.4)1 (2.3)0.202Preoperative use of digoxin20 (45.5)20 (45.5)\>0.999Type of operation0.616 Mitral valve surgery8 (18.2)11 (25.0) Aortic valve surgery15 (34.1)15 (34.1) Mitral + aortic valve surgery13 (29.5)8 (18.2) CABG+ valve surgery1 (2.3)3 (6.8) Other cardiac surgery7 (15.9)7 (15.9)Cardiopulmonary bypass time, minutes68.8 (53.8--93.6)73.5 (55.7--85.1)0.635Cross-clamp time, minutes47.3 (36.6--67.1)50.7 (34.2--62.4)0.892Defibrillation after reperfusion14 (31.8)18 (40.9)0.507Temporary pacemaker insertion^a^7 (15.9)6 (13.6)\>0.999Data are presented as the median (interquartile range) or number (%). ^a^Ventricular pacing. *CABG* coronary artery bypass graft

There were 22 patients who had AF during the first 96 h after cardiac surgery with CPB. Patients assigned to receive dexmedetomidine were significantly less likely to have AF than patients assigned to receive propofol (6 (13.6 %) vs 16 (36.4 %); odds ratio, 0.28; 95 % confidence interval, 0.10, 0.80; *P* = 0.025; number needed to treat, 4.4) (Table [2](#Tab2){ref-type="table"}). The relative risk reduction was 62.6 %. The Kaplan-Meier incidence of postoperative AF in the dexmedetomidine group and propofol group is shown in Fig. [2](#Fig2){ref-type="fig"}. In patients who had received dexmedetomidine, the median onset of AF tended to be delayed compared with control patients (Table [2](#Tab2){ref-type="table"}).Table 2Postoperative characteristics and resource utilization of the patient groupsCharacteristicsPropofol (*n* = 44)Dexmedetomidine (*n* = 44)*P* valueAF during 96 h after surgery16 (36.4)6 (13.6)0.025Onset of AF (h after operation)25.5 (19.5--36.4)40.4 (19.3--53.1)0.261In-hospital mortality1 (2.3)0 (0)\>0.999Mortality during study period1 (2.3)0 (0)\>0.999Serum potassium before AF, mmol/L4.2 (3.9--4.3)4.0 (3.--4.1)0.083Peak postoperative cTnI, ng/mL5.5 (2.9--9.5)6.9 (2.6--11.8)0.611Hypotension13 (29.5)25 (56.8)0.017Bradycardia1 (2.3)4 (9.1)0.360Nausea/vomiting10 (22.7)9 (20.5)\>0.999Delirium5 (11.4)0 (0)0.055Acute kidney injury3 (6.8)5 (11.4)0.713Mechanical ventilation ≥24 h6 (13.6)4 (9.1)0.739Intubation time, h21.2 (17.0--22.8)21.0 (16.9--22.5)0.757Length of ICU stay, days3.5 (2.7--4.5)2.9 (2.4--3.5)0.008Length of hospital stay, days14.0 (11.0--17.0)13.5 (11.3--17.0)0.983Postoperative hospital days8.0 (7.0--10.0)8.0 (7.0--9.8)0.505Hospital fees, Chinese yuan, ×10^4^8.64 (7.32--9.63)7.79 (6.72--9.05)0.068Data are presented as the number (%) or median (interquartile range). *AF* atrial fibrillation, *cTnI* cardiac troponin I, *ICU* intensive care unitFig. 2Kaplan-Meier incidence of postoperative atrial fibrillation according to treatment group

One patient in the propofol group died on the second postoperative day due to cardiac failure. There were no statistically significant differences between the groups in peak postoperative cardiac troponin I (cTnI), bradycardia, nausea and vomiting, mechanical ventilation ≥24 h, acute kidney injury, or delirium (Table [2](#Tab2){ref-type="table"}). However, the incidence of hypotension was significantly higher in the dexmedetomidine group than in the propofol group (Table [2](#Tab2){ref-type="table"}). Patients with hypotension recovered quickly after intravenous fluid replacement and/or adjusting the infusion speed of vasoactive drugs. The details of sedation and analgesia are reflected in Table [3](#Tab3){ref-type="table"}.Table 3Details of sedation and analgesia in propofol and dexmedetomidine groupsPropofol (*n* = 44)Dexmedetomidine (*n* = 44)*P* valueRASS at 4 h-2 (-3 to -1)-2 (-2 to -1)0.488VAS at 24 h1.0 (1-2)1.5 (1-2)0.935Extra analgesic requirements^a^4 (9.1)5 (11.4)\>0.999Infusion speed at 4 h, mg/kg/h or μg/kg/h0.98 (0.77 to 1.23)0.68 (0.48 to 0.82)Total dosage, mg or μg900 (625 to 1100)572 (448 to 720)Infusion time, minutes889 (645 to 1000)870 (725 to 1019)0.537Data are presented as the median (interquartile range) or n (%). ^a^Number of patients who received extra analgesic treatment within 24 h after surgery. *RASS* Richmond agitation-sedation scale, *VAS* visual analog scale

Medical resource utilization is also reported in Table [2](#Tab2){ref-type="table"}. Although the intubation time, length of hospital stay and postoperative hospital days were similar in the two groups, the length of ICU stay was significantly shorter in the dexmedetomidine group than in the propofol group (2.9 (2.4--3.5) vs 3.5 (2.7--4.5 days, *P* = 0.008), with a trend toward a decrease in median hospital fees (86,367 vs 77,874 Chinese yuan, *P* = 0.068). Patients who experienced postoperative AF were significantly older and had a longer ICU stay, more postoperative hospital days and higher hospital fees compared to patients without postoperative AF (Table [4](#Tab4){ref-type="table"}).Table 4Comparison of patients with and without atrial fibrillation (AF) or flutterCharacteristicsPatients with AF (*n* = 22)Patients without AF (*n* = 66)*P* valueAge, years62.5 (57.8--68.3)52.0 (45.5--61.0)\<0.001Female gender, *n* (%)16 (72.7)37 (56.1)0.212Body mass index, kg/m^2^23.4 (20.9--27.1)22.2 (19.8--24.0)0.124Cardiopulmonary bypass time, minutes74.7 (61.0--96.0)68.8 (55.2--85.1)0.527Cross-clamp time, minutes48.5 (40.6--64.1)48.2 (33.8--64.6)0.643Intubation time, h21.2 (16.6--22.8)21.0 (17.3--22.5)0.528Length of ICU stay, days3.8 (2.9--4.8)2.9 (2.4--3.7)0.002Length of hospital stay, days15.0 (13.0--17.5)13.0 (11.0--16.0)0.117Postoperative hospital days9.5 (8.0--11.0)8.0 (7.0--9.0)0.021Hospital fees, Chinese yuan, ×10^4^8.91 (8.10--10.22)7.80 (6.69--9.13)0.006Data are presented as the median (interquartile range) unless otherwise stated. *ICU* intensive care unit

Discussion {#Sec8}
==========

To our knowledge, the current study is the first prospective randomized trial confirming that dexmedetomidine sedation reduces new-onset postoperative AF and shortens the length of ICU stay with a trend toward a decrease in hospital costs, compared to propofol sedation. The absolute risk reduction for AF was 22.8 % in patients following cardiac surgery, with a number needed to treat of 4.4, suggesting that dexmedetomidine administration during the early postoperative period could prevent one case of AF for every five patients. In addition, our results also demonstrated that postoperative AF was associated with a longer stay in the ICU, more postoperative hospital days and increased hospital fees.

Dexmedetomidine is an α~2~ adrenergic receptor agonist that induces sedative, anxiolytic and analgesic effects without causing respiratory depression \[[@CR18], [@CR29]\] and has been increasingly used for sedation in cardiac surgery patients \[[@CR16], [@CR29]\]. A small retrospective study (*n* = 45) reported that patients undergoing cardiovascular surgery who received dexmedetomidine were less likely to have new-onset AF than patients who did not receive any sedative drugs \[[@CR22]\], which supports the results of the current study. However, a recent meta-analysis showed that dexmedetomidine was not associated with a decrease in the incidence of postoperative AF in patients undergoing cardiac surgery \[[@CR30]\]. The potential reasons for this inconsistency may be the fact that postoperative AF was not the primary outcome, an explicit and consistent definition of AF was lacking, different observation periods were used for detecting AF, a large variety of types of surgery and drug regimens were included in those studies \[[@CR31]--[@CR36]\], and patients with prior AF were not excluded in most studies \[[@CR31]--[@CR35]\]. Some patients had a history of chronic, recurrent AF that was resistant to chemical cardioversion \[[@CR18]\]. Consequently, the inclusion of patients with prior AF in the study may have concealed the efficacy of dexmedetomidine to reduce postoperative AF.

Several potential factors could contribute to the effect of dexmedetomidine on preventing new-onset postoperative AF. First, dexmedetomidine could reduce myocardial ischemia-reperfusion injury and improve the perfusion of the myocardium in patients undergoing cardiac surgery \[[@CR16], [@CR36]\]. Second, the inflammatory response induced by cardiac surgery and bypass can alter atrial electrophysiology and structural substrates, leading to increased vulnerability to AF \[[@CR14], [@CR37]\]. Dexmedetomidine has been shown to inhibit the inflammatory response in animal models \[[@CR38], [@CR39]\] and in clinical trials \[[@CR40], [@CR41]\]. Tasdogan et al. \[[@CR41]\] found that postoperative patients who received dexmedetomidine had significantly lower levels of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 than those who received propofol. Third, increased adrenergic tone plays a role in the development of postoperative AF \[[@CR42]\]. Dexmedetomidine can decrease catecholamines \[[@CR43]\] and inhibit the arrhythmogenic effect of epinephrine \[[@CR44]\]. Fourth, dexmedetomidine can enhance vagal activity, leading to alterations in Ca^2+^ currents across the myocyte cell membrane, which in turn could result in prolonged repolarization and an increased effective refractory period \[[@CR17]\]. Based on the combination of organ-protective, anti-inflammatory, sympatholytic and parasympathomimetic effects, it is not surprising that the use of dexmedetomidine during the early postoperative period could be beneficial in preventing AF after cardiac surgery.

An increased risk of bradycardia and hypotension can be a concern of dexmedetomidine \[[@CR23], [@CR24]\]. In this study, hypotension was more common among dexmedetomidine-treated patients despite the similar levels of sedation attained by patients treated with dexmedetomidine and propofol. However, hypotension was quickly rectified after intravenous fluid replacement and/or adjusting the infusion speed of the vasoactive or sedative drug, which rarely necessitated stopping the study in either group.

This study has several limitations. Fist, there was no blinding of the propofol and dexmedetomidine infusions in our study. However, the diagnosis of AF was made by continuous electrocardiogram (ECG) monitoring and/or 12-lead ECG, and the practitioners who identified AF were not aware of the study objectives.

Second, routine prophylactic strategies for postoperative AF, such as the perioperative use of β-blockers, were not implemented in our study. The choice of antiarrhythmic medications was left to the discretion of the attending physicians, but physicians chose drugs according to local guidelines. For example, digitalis was usually used to slow the ventricular rate during AF in our ICU. Furthermore, the attending physicians were also unaware of the study objectives. More patients received digitalis in the propofol group than in the dexmedetomidine group (see Additional file [1](#MOESM1){ref-type="media"}), which is mostly due to a greater number of postoperative AF incidents among patients receiving propofol.

Third, although the elderly patients were more likely to have postoperative AF, the patients in this study were younger than those in most other studies (mean age, 54 vs approximately 65 years) \[[@CR1], [@CR3], [@CR31]\]. Moreover, only 16 patients in our study (18.2 %) were ≥65 years old. Therefore, additional studies are needed to investigate the effects of dexmedetomidine on the prevention of postoperative AF in elderly patients after cardiac surgery.

Fourth, tests about the secondary end points (e.g., the length of ICU stay) and the incidence of adverse events (e.g., hypotension) were performed without adjusting for multiple testing in this study. Therefore, these results are explorative and confirmatory studies are needed. However, our primary endpoint, the incidence of postoperative AF, was a single primary endpoint and therefore no adjustments are needed \[[@CR45]\].

Conclusions {#Sec9}
===========

Our results demonstrated that the use of dexmedetomidine might be efficacious in the prevention of postoperative AF and could be beneficial in reducing medical resource utilization in patients after cardiac surgery. Larger RCTs are needed to confirm our findings.

Key messages {#Sec10}
============

Patients with new onset postoperative AF were significantly older and had a longer ICU stay, more postoperative hospital days and increased hospital feesDexmedetomidine sedation reduced new-onset postoperative AF and shortened the ICU stay in patients after cardiac surgery compared to propofol sedationThe administration of dexmedetomidine during the early postoperative period could prevent one case of AF for every five patients undergoing cardiac surgery

Additional file {#Sec11}
===============

Additional file 1: Table S1.Postoperative medication use of the patients in propofol and dexmedetomidine groups. Description of data: medications were used within 96 h after cardiac surgery (DOCX 13 kb)
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